NEW YORK – Becton Dickinson revealed last week that it has acquired NAT Diagnostics, a molecular diagnostics firm focused on rapid point-of-care testing. The NAT Dx isothermal technology will be further developed by BD with an eye toward offering customers decentralized molecular testing options in early 2023.

The deal was signed last year, according to BD, but it was not finalized until last quarter. Terms of the agreement have not been disclosed.